vs
Idexx Laboratories（IDXX）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是Idexx Laboratories的1.2倍（$1.3B vs $1.1B），Idexx Laboratories净利率更高（22.8% vs -63.1%，领先85.8%），Idexx Laboratories同比增速更快（14.3% vs -25.8%），Idexx Laboratories自由现金流更多（$326.3M vs $-1.1B），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs 3.3%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
IDXX vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.2倍
$1.1B
营收增速更快
IDXX
高出40.1%
-25.8%
净利率更高
IDXX
高出85.8%
-63.1%
自由现金流更多
IDXX
多$1.5B
$-1.1B
两年增速更快
IDXX
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.3B |
| 净利润 | $248.2M | $-811.0M |
| 毛利率 | 60.3% | 9.3% |
| 营业利润率 | 28.9% | -64.8% |
| 净利率 | 22.8% | -63.1% |
| 营收同比 | 14.3% | -25.8% |
| 净利润同比 | 14.8% | -9.0% |
| 每股收益（稀释后） | $3.09 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXRIVN
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $998.4M | $1.2B | ||
| Q4 24 | $954.3M | $1.7B | ||
| Q3 24 | $975.5M | $874.0M | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $964.1M | $1.2B |
净利润IDXXRIVN
| Q4 25 | $248.2M | $-811.0M | ||
| Q3 25 | $274.6M | $-1.2B | ||
| Q2 25 | $294.0M | $-1.1B | ||
| Q1 25 | $242.7M | $-545.0M | ||
| Q4 24 | $216.1M | $-744.0M | ||
| Q3 24 | $232.8M | $-1.1B | ||
| Q2 24 | $203.3M | $-1.5B | ||
| Q1 24 | $235.6M | $-1.4B |
毛利率IDXXRIVN
| Q4 25 | 60.3% | 9.3% | ||
| Q3 25 | 61.8% | 1.5% | ||
| Q2 25 | 62.6% | -15.8% | ||
| Q1 25 | 62.4% | 16.6% | ||
| Q4 24 | 59.8% | 9.8% | ||
| Q3 24 | 61.1% | -44.9% | ||
| Q2 24 | 61.7% | -38.9% | ||
| Q1 24 | 61.5% | -43.8% |
营业利润率IDXXRIVN
| Q4 25 | 28.9% | -64.8% | ||
| Q3 25 | 32.1% | -63.1% | ||
| Q2 25 | 33.6% | -85.5% | ||
| Q1 25 | 31.7% | -52.8% | ||
| Q4 24 | 27.4% | -38.1% | ||
| Q3 24 | 31.2% | -133.8% | ||
| Q2 24 | 26.3% | -118.7% | ||
| Q1 24 | 31.0% | -123.3% |
净利率IDXXRIVN
| Q4 25 | 22.8% | -63.1% | ||
| Q3 25 | 24.8% | -75.3% | ||
| Q2 25 | 26.5% | -85.7% | ||
| Q1 25 | 24.3% | -44.0% | ||
| Q4 24 | 22.7% | -42.9% | ||
| Q3 24 | 23.9% | -125.9% | ||
| Q2 24 | 20.3% | -125.8% | ||
| Q1 24 | 24.4% | -120.1% |
每股收益（稀释后）IDXXRIVN
| Q4 25 | $3.09 | $-0.66 | ||
| Q3 25 | $3.40 | $-0.96 | ||
| Q2 25 | $3.63 | $-0.97 | ||
| Q1 25 | $2.96 | $-0.48 | ||
| Q4 24 | $2.62 | $-0.67 | ||
| Q3 24 | $2.80 | $-1.08 | ||
| Q2 24 | $2.44 | $-1.46 | ||
| Q1 24 | $2.81 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $6.1B |
| 总债务越低越好 | $450.0M | — |
| 股东权益账面价值 | $1.6B | $4.6B |
| 总资产 | $3.4B | $14.9B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资IDXXRIVN
| Q4 25 | $180.1M | $6.1B | ||
| Q3 25 | $208.2M | $7.1B | ||
| Q2 25 | $164.6M | $7.5B | ||
| Q1 25 | $164.0M | $7.2B | ||
| Q4 24 | $288.3M | $7.7B | ||
| Q3 24 | $308.6M | $6.7B | ||
| Q2 24 | $401.6M | $7.9B | ||
| Q1 24 | $397.4M | $7.9B |
总债务IDXXRIVN
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.4B |
股东权益IDXXRIVN
| Q4 25 | $1.6B | $4.6B | ||
| Q3 25 | $1.6B | $5.1B | ||
| Q2 25 | $1.5B | $6.1B | ||
| Q1 25 | $1.4B | $6.2B | ||
| Q4 24 | $1.6B | $6.6B | ||
| Q3 24 | $1.6B | $5.9B | ||
| Q2 24 | $1.6B | $6.8B | ||
| Q1 24 | $1.6B | $8.1B |
总资产IDXXRIVN
| Q4 25 | $3.4B | $14.9B | ||
| Q3 25 | $3.4B | $15.2B | ||
| Q2 25 | $3.3B | $15.6B | ||
| Q1 25 | $3.2B | $15.5B | ||
| Q4 24 | $3.3B | $15.4B | ||
| Q3 24 | $3.4B | $14.3B | ||
| Q2 24 | $3.4B | $15.4B | ||
| Q1 24 | $3.4B | $15.7B |
负债/权益比IDXXRIVN
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $-1.1B |
| 自由现金流率自由现金流/营收 | 29.9% | -89.0% |
| 资本支出强度资本支出/营收 | 2.7% | 36.0% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $1.1B | $-2.5B |
8季度趋势，按日历期对齐
经营现金流IDXXRIVN
| Q4 25 | $355.8M | $-681.0M | ||
| Q3 25 | $402.3M | $26.0M | ||
| Q2 25 | $185.7M | $64.0M | ||
| Q1 25 | $238.0M | $-188.0M | ||
| Q4 24 | $262.0M | $1.2B | ||
| Q3 24 | $220.1M | $-876.0M | ||
| Q2 24 | $248.3M | $-754.0M | ||
| Q1 24 | $198.6M | $-1.3B |
自由现金流IDXXRIVN
| Q4 25 | $326.3M | $-1.1B | ||
| Q3 25 | $371.2M | $-421.0M | ||
| Q2 25 | $151.6M | $-398.0M | ||
| Q1 25 | $207.9M | $-526.0M | ||
| Q4 24 | $232.8M | $856.0M | ||
| Q3 24 | $192.0M | $-1.2B | ||
| Q2 24 | $215.0M | $-1.0B | ||
| Q1 24 | $168.3M | $-1.5B |
自由现金流率IDXXRIVN
| Q4 25 | 29.9% | -89.0% | ||
| Q3 25 | 33.6% | -27.0% | ||
| Q2 25 | 13.7% | -30.5% | ||
| Q1 25 | 20.8% | -42.4% | ||
| Q4 24 | 24.4% | 49.4% | ||
| Q3 24 | 19.7% | -131.9% | ||
| Q2 24 | 21.4% | -89.6% | ||
| Q1 24 | 17.5% | -126.5% |
资本支出强度IDXXRIVN
| Q4 25 | 2.7% | 36.0% | ||
| Q3 25 | 2.8% | 28.7% | ||
| Q2 25 | 3.1% | 35.5% | ||
| Q1 25 | 3.0% | 27.3% | ||
| Q4 24 | 3.1% | 18.9% | ||
| Q3 24 | 2.9% | 31.7% | ||
| Q2 24 | 3.3% | 24.4% | ||
| Q1 24 | 3.1% | 21.1% |
现金转化率IDXXRIVN
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.21× | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
